NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Real-World Effectiveness and Safety of Pegcetacoplan in Patients With C3G or IC-MPG: A Multi-Country Study

RecruitingPhase 4

Sponsor: Swedish Orphan Biovitrum

Conditions: C3 Glomerulopathy (C3G), Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN)

Interventions: Pegcetacoplan

Countries: Australia, Austria, Belgium, Canada, Czechia, France, Germany, Italy

The purpose of this study is to evaluate the effectiveness and safety of Pegcetacoplan in patients with C3G and primary IC-MPGN in the real-world setting. This study will also assess biomarkers not routinely measured in clinical practice. Results will support the long-term evaluation of the benefit-risk profile of pegcetacoplan in a broad patient population, informing clinical decision-making.

Eligibility overview

Sex: ALL

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria

Inclusion Criteria:

* Have received or plan to receive pegcetacoplan for the treatment of C3G or primary IC-MPGN.
* Provided signed and dated informed consent. For participants under the legal age signed and dated informed consent is provided by the participant's legally authorised representative. Assent will also be obtained from paediatric participants as required by local regulations.

Exclusion Criteria:

* Receiving an investigational treatment for C3G or primary IC-MPGN at the time of pegcetacoplan initiation.
* Initiated treatment with pegcetacoplan in an interventional study.

Locations (101)

Kingswood, Australia
Woolloongabba, Australia
Graz, Austria
Innsbruck, Austria
Vienna, Austria
Vienna, Austria
Brussels, Belgium
Edegem, Belgium
Gilly, Belgium
Leuven, Belgium
Liège, Belgium
Namur, Belgium
Calgary, Alberta, Canada
Vancouver, British Columbia, Canada
Kingston, Ontario, Canada
London, Ontario, Canada
Toronto, Ontario, Canada
Toronto, Ontario, Canada
Montreal, Quebec, Canada
Montreal, Quebec, Canada
Prague, Czechia
Prague, Czechia
Bordeaux, France
Bron, France
Créteil, France
Lille, France
Marseille, France
Montpellier, France
Nantes, France
Paris, France
+ 71 more on CT.gov